Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2)
SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 agent that has advanced in clinical development. We validate the potent antiviral efficacy of niclosamide in a SARS-CoV-2 hu...
Gespeichert in:
| Veröffentlicht in: | PloS one 2021-12, Vol.16 (12), p.e0260958 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 |
| container_start_page | e0260958 |
| container_title | PloS one |
| container_volume | 16 |
| creator | Weiss, Anne Touret, Franck Baronti, Cecile Gilles, Magali Hoen, Bruno Nougairède, Antoine de Lamballerie, Xavier Sommer, Morten O. A. |
| description | SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 agent that has advanced in clinical development. We validate the potent antiviral efficacy of niclosamide in a SARS-CoV-2 human airway model. Furthermore, niclosamide remains its potency against the D614G, Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants. Our data further support the potent anti-SARS-CoV-2 properties of niclosamide and highlights its great potential as a therapeutic agent for COVID-19. |
| doi_str_mv | 10.1371/journal.pone.0260958 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_plos_</sourceid><recordid>TN_cdi_plos_journals_2605599426</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_212ecde653b84f1893790a4ab2a5a304</doaj_id><sourcerecordid>2605599426</sourcerecordid><originalsourceid>FETCH-LOGICAL-c537t-11ea0e0ecee9ff8146f6fb8fb65e9540089084e272d79e47234ef49f866aab8e3</originalsourceid><addsrcrecordid>eNp1UtuO0zAQjRCIXRb-AAlLvFCJFN8TvyB1y2VXqkBigVdrkozbVGlc7LSrfhz_hrsNiEVCfhh75pwz9vFk2XNGp0wU7M3a70IP3XTre5xSrqlR5YPsnBnBc82pePjX_ix7EuOaUiVKrR9nZ0KWShkqz7Ofn9q68xE2bYMkrvxtJHEIvl8S6Id23wboCNTH3XAgbU-ArHYbSLENt3AgG99gR7wjN7MvN_ncf895QjlMDJ9AfZMIte8jhj02ZOsH7OsDgSW0fRzIsEIy67YrIK8upyytYvKaXOIwnoVikzuNd9il3B5Cmy51qmlWTPnkafbIQRfx2Rgvsm8f3n-dX-WLzx-v57NFXitRDDljCBQp1ojGuZJJ7bSrSldphUZJSktDS4m84E1hUBZcSHTSuGQWQFWiuMhenHS3ySs7Oh9tMj3ZaCTXCXF9QjQe1nYb2g2Eg_XQ2ruED0sLYUheo-WMY92gVqIqpWOlEYWhIKHioEBQmbTejt121QabGvshfcM90fuVvl3Zpd_bUgtDi6PA5CSw-od2NVvYY45KbrRias8S9uXYLPgfO4zDf54nT6g6-BgDuj-yjNrjOP5m2eM42nEcxS-j5tDY</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2605599426</pqid></control><display><type>article</type><title>Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2)</title><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Weiss, Anne ; Touret, Franck ; Baronti, Cecile ; Gilles, Magali ; Hoen, Bruno ; Nougairède, Antoine ; de Lamballerie, Xavier ; Sommer, Morten O. A.</creator><contributor>Polyak, Stephen J.</contributor><creatorcontrib>Weiss, Anne ; Touret, Franck ; Baronti, Cecile ; Gilles, Magali ; Hoen, Bruno ; Nougairède, Antoine ; de Lamballerie, Xavier ; Sommer, Morten O. A. ; Polyak, Stephen J.</creatorcontrib><description>SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 agent that has advanced in clinical development. We validate the potent antiviral efficacy of niclosamide in a SARS-CoV-2 human airway model. Furthermore, niclosamide remains its potency against the D614G, Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants. Our data further support the potent anti-SARS-CoV-2 properties of niclosamide and highlights its great potential as a therapeutic agent for COVID-19.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0260958</identifier><identifier>PMID: 34855904</identifier><language>eng</language><publisher>San Francisco: Public Library of Science</publisher><subject>Antiviral activity ; Antiviral drugs ; Authorship ; Biology and life sciences ; Chemical compounds ; Coronaviruses ; COVID-19 ; Cytotoxicity ; Disease transmission ; Genomes ; Infections ; Life Sciences ; Medicine and health sciences ; Microbiology and Parasitology ; Niclosamide ; Pharmacology ; Research and Analysis Methods ; Respiratory tract ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Statistical analysis ; Vaccines ; Virology</subject><ispartof>PloS one, 2021-12, Vol.16 (12), p.e0260958</ispartof><rights>2021 Weiss et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><rights>2021 Weiss et al 2021 Weiss et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c537t-11ea0e0ecee9ff8146f6fb8fb65e9540089084e272d79e47234ef49f866aab8e3</citedby><cites>FETCH-LOGICAL-c537t-11ea0e0ecee9ff8146f6fb8fb65e9540089084e272d79e47234ef49f866aab8e3</cites><orcidid>0000-0003-4005-5674 ; 0000-0002-4734-2249</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639074/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639074/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://amu.hal.science/hal-04296515$$DView record in HAL$$Hfree_for_read</backlink></links><search><contributor>Polyak, Stephen J.</contributor><creatorcontrib>Weiss, Anne</creatorcontrib><creatorcontrib>Touret, Franck</creatorcontrib><creatorcontrib>Baronti, Cecile</creatorcontrib><creatorcontrib>Gilles, Magali</creatorcontrib><creatorcontrib>Hoen, Bruno</creatorcontrib><creatorcontrib>Nougairède, Antoine</creatorcontrib><creatorcontrib>de Lamballerie, Xavier</creatorcontrib><creatorcontrib>Sommer, Morten O. A.</creatorcontrib><title>Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2)</title><title>PloS one</title><description>SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 agent that has advanced in clinical development. We validate the potent antiviral efficacy of niclosamide in a SARS-CoV-2 human airway model. Furthermore, niclosamide remains its potency against the D614G, Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants. Our data further support the potent anti-SARS-CoV-2 properties of niclosamide and highlights its great potential as a therapeutic agent for COVID-19.</description><subject>Antiviral activity</subject><subject>Antiviral drugs</subject><subject>Authorship</subject><subject>Biology and life sciences</subject><subject>Chemical compounds</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Cytotoxicity</subject><subject>Disease transmission</subject><subject>Genomes</subject><subject>Infections</subject><subject>Life Sciences</subject><subject>Medicine and health sciences</subject><subject>Microbiology and Parasitology</subject><subject>Niclosamide</subject><subject>Pharmacology</subject><subject>Research and Analysis Methods</subject><subject>Respiratory tract</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Statistical analysis</subject><subject>Vaccines</subject><subject>Virology</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNp1UtuO0zAQjRCIXRb-AAlLvFCJFN8TvyB1y2VXqkBigVdrkozbVGlc7LSrfhz_hrsNiEVCfhh75pwz9vFk2XNGp0wU7M3a70IP3XTre5xSrqlR5YPsnBnBc82pePjX_ix7EuOaUiVKrR9nZ0KWShkqz7Ofn9q68xE2bYMkrvxtJHEIvl8S6Id23wboCNTH3XAgbU-ArHYbSLENt3AgG99gR7wjN7MvN_ncf895QjlMDJ9AfZMIte8jhj02ZOsH7OsDgSW0fRzIsEIy67YrIK8upyytYvKaXOIwnoVikzuNd9il3B5Cmy51qmlWTPnkafbIQRfx2Rgvsm8f3n-dX-WLzx-v57NFXitRDDljCBQp1ojGuZJJ7bSrSldphUZJSktDS4m84E1hUBZcSHTSuGQWQFWiuMhenHS3ySs7Oh9tMj3ZaCTXCXF9QjQe1nYb2g2Eg_XQ2ruED0sLYUheo-WMY92gVqIqpWOlEYWhIKHioEBQmbTejt121QabGvshfcM90fuVvl3Zpd_bUgtDi6PA5CSw-od2NVvYY45KbrRias8S9uXYLPgfO4zDf54nT6g6-BgDuj-yjNrjOP5m2eM42nEcxS-j5tDY</recordid><startdate>20211202</startdate><enddate>20211202</enddate><creator>Weiss, Anne</creator><creator>Touret, Franck</creator><creator>Baronti, Cecile</creator><creator>Gilles, Magali</creator><creator>Hoen, Bruno</creator><creator>Nougairède, Antoine</creator><creator>de Lamballerie, Xavier</creator><creator>Sommer, Morten O. A.</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4005-5674</orcidid><orcidid>https://orcid.org/0000-0002-4734-2249</orcidid></search><sort><creationdate>20211202</creationdate><title>Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2)</title><author>Weiss, Anne ; Touret, Franck ; Baronti, Cecile ; Gilles, Magali ; Hoen, Bruno ; Nougairède, Antoine ; de Lamballerie, Xavier ; Sommer, Morten O. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c537t-11ea0e0ecee9ff8146f6fb8fb65e9540089084e272d79e47234ef49f866aab8e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antiviral activity</topic><topic>Antiviral drugs</topic><topic>Authorship</topic><topic>Biology and life sciences</topic><topic>Chemical compounds</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Cytotoxicity</topic><topic>Disease transmission</topic><topic>Genomes</topic><topic>Infections</topic><topic>Life Sciences</topic><topic>Medicine and health sciences</topic><topic>Microbiology and Parasitology</topic><topic>Niclosamide</topic><topic>Pharmacology</topic><topic>Research and Analysis Methods</topic><topic>Respiratory tract</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Statistical analysis</topic><topic>Vaccines</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weiss, Anne</creatorcontrib><creatorcontrib>Touret, Franck</creatorcontrib><creatorcontrib>Baronti, Cecile</creatorcontrib><creatorcontrib>Gilles, Magali</creatorcontrib><creatorcontrib>Hoen, Bruno</creatorcontrib><creatorcontrib>Nougairède, Antoine</creatorcontrib><creatorcontrib>de Lamballerie, Xavier</creatorcontrib><creatorcontrib>Sommer, Morten O. A.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weiss, Anne</au><au>Touret, Franck</au><au>Baronti, Cecile</au><au>Gilles, Magali</au><au>Hoen, Bruno</au><au>Nougairède, Antoine</au><au>de Lamballerie, Xavier</au><au>Sommer, Morten O. A.</au><au>Polyak, Stephen J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2)</atitle><jtitle>PloS one</jtitle><date>2021-12-02</date><risdate>2021</risdate><volume>16</volume><issue>12</issue><spage>e0260958</spage><pages>e0260958-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 agent that has advanced in clinical development. We validate the potent antiviral efficacy of niclosamide in a SARS-CoV-2 human airway model. Furthermore, niclosamide remains its potency against the D614G, Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants. Our data further support the potent anti-SARS-CoV-2 properties of niclosamide and highlights its great potential as a therapeutic agent for COVID-19.</abstract><cop>San Francisco</cop><pub>Public Library of Science</pub><pmid>34855904</pmid><doi>10.1371/journal.pone.0260958</doi><orcidid>https://orcid.org/0000-0003-4005-5674</orcidid><orcidid>https://orcid.org/0000-0002-4734-2249</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2021-12, Vol.16 (12), p.e0260958 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2605599426 |
| source | DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Antiviral activity Antiviral drugs Authorship Biology and life sciences Chemical compounds Coronaviruses COVID-19 Cytotoxicity Disease transmission Genomes Infections Life Sciences Medicine and health sciences Microbiology and Parasitology Niclosamide Pharmacology Research and Analysis Methods Respiratory tract Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Statistical analysis Vaccines Virology |
| title | Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T14%3A19%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Niclosamide%20shows%20strong%20antiviral%20activity%20in%20a%20human%20airway%20model%20of%20SARS-CoV-2%20infection%20and%20a%20conserved%20potency%20against%20the%20Alpha%20(B.1.1.7),%20Beta%20(B.1.351)%20and%20Delta%20variant%20(B.1.617.2)&rft.jtitle=PloS%20one&rft.au=Weiss,%20Anne&rft.date=2021-12-02&rft.volume=16&rft.issue=12&rft.spage=e0260958&rft.pages=e0260958-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0260958&rft_dat=%3Cproquest_plos_%3E2605599426%3C/proquest_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2605599426&rft_id=info:pmid/34855904&rft_doaj_id=oai_doaj_org_article_212ecde653b84f1893790a4ab2a5a304&rfr_iscdi=true |